Kayothera has developed a pipeline of first-in-class, exceptionally safe, oral retinoid pathway antagonists that offer a unique platform to treat various cardiometabolic diseases and cancer. Therapies in Kayothera’s pipeline inhibit distinct enzymes in the retinoid pathway that drive disease progression in type 2 diabetes and obesity, while other pipeline therapies reverse immune suppression in multiple genetically defined and high-need cancer types. The lead program, KAYO-1609, is currently in IND-enabling studies to support a Phase 1 trial in early 2025 in healthy patients, while additional programs are slated for clinical entry in 2026.